93
Participants
Start Date
September 30, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
ADX-N05
150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
Placebo
One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
Center for Sleep Medicine, Philadelphia
The Center for Sleep and Wake Disorders, Chevy Chase
Pulmonary and Critical Care Associates of Baltimore, Towson
Rex Sleep Disorders Center, Raleigh
Wake Research Associates, Raleigh
SleepMed of South Carolina, Columbia
NeuroTrials Research, Inc., Atlanta
Sleep Disorders Center of Georgia, Atlanta
SleepMed of Central Georgia, Macon
PAB Clinical Research, Brandon
Clinical Research Group of St. Petersburg, St. Petersburg
Sleep Disorders Center of Alabama, Birmingham
Kentucky Research Group, Louisville
Community Research, Crestview Hills
Mercy St. Vincent Medical Center, Toledo
Minnesota Lung Center and Sleep Institute, Edina
Chicago Research Center, Chicago
Washington University, St Louis
Metroplex Pulmonary and Sleep Center, McKinney
Sleep Medicine Associates of Texas, Dallas
Todd J. Swick, MD, PA, Houston
Sleep Therapy and Research Center, San Antonio
Future Search Trials of Neurology, Austin
Sleep-Alertness Disorders Center, Aurora
Pulmonary Associates, Phoenix
Pacific Research Network, San Diego
Stanford Sleep Medicine Center, Redwood City
Neurocare, Inc., Newton
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY